Childhood Burkitt Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
TP53 pathway analysis in paediatric Burkitt lymphoma reveals increased MDM4 expression as the only TP53 pathway abnormality detected in a subset of cases.
|
22845047 |
2012 |
Childhood Burkitt Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A panel of 12 Burkitt's lymphoma cell lines and four other B cell lines were tested for the presence of mutations in p53.
|
1915267 |
1991 |
Childhood Burkitt Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A previous study showed that this is the case in some Burkitt lymphoma (BL) cell lines, where enhanced translation of mdm2 messenger RNA results in overexpression of the protein that complexes and inactivates wild-type p53.
|
11159535 |
2001 |
Childhood Burkitt Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Activation of endogenous wt p53 in BLs and lymphoblastoid cell lines led to the induction of SAP and this was inhibited by the specific p53 inhibitor pifithrin-alpha.
|
15378026 |
2004 |
Childhood Burkitt Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
At least 60% of BL cell lines carry a mutated p53 gene as well.
|
8502475 |
1993 |
Childhood Burkitt Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
At least three genetic changes are known to contribute to the genesis of Burkitt's lymphoma (BL): the Ig/myc translocation, the presence of Epstein-Barr virus (EBV) in the vast majority of the endemic and a minority of sporadic tumors, and a p53 mutation, present in approximately 60% of the BL-derived lines.
|
8276258 |
1993 |
Childhood Burkitt Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Biological activities of p53 mutants in Burkitt's lymphoma cells.
|
8492087 |
1993 |
Childhood Burkitt Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Cells from acute lymphoblastic leukemia (ALL) and Burkitt's lymphoma cell lines express elevated levels of p53, while all examined human acute myeloid leukemia cell lines synthesize negligible p53 protein.
|
2140591 |
1990 |
Childhood Burkitt Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Clinical significance of detecting p53 protein in Burkitt lymphoma and B-cell acute lymphoblastic leukemia using immunocytochemistry.
|
9613990 |
1998 |
Childhood Burkitt Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Combined loss of p53 induction and function due to miRNA-mediated regulation of ATM and NLK, together with the upregulation of TFAP4, may be a central role for human miRNAs in eBL oncogenesis.
|
29132323 |
2017 |
Childhood Burkitt Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
DZ-CIS downregulated c-myc and overcame CIS resistance in myc-driven TP53-mutated aggressive B cell Burkitt lymphoma.
|
30840322 |
2019 |
Childhood Burkitt Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Flavopiridol induces apoptosis and caspase-3 activation of a newly characterized Burkitt's lymphoma cell line containing mutant p53 genes.
|
11482875 |
2002 |
Childhood Burkitt Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Further analysis of the BL lines in which p53 had been characterized showed that whereas some lines were essentially resistant to cisplatin, three were rapidly induced to undergo apoptosis.
|
7588628 |
1995 |
Childhood Burkitt Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here we show that chloroquine, a drug that activates the stress-responsive Atm-p53 tumor-suppressor pathway, preferentially enhances the death of Myc oncogene-overexpressing primary mouse B cells and mouse embryonic fibroblasts (MEFs) and impairs Myc-induced lymphomagenesis in a transgenic mouse model of human Burkitt lymphoma.
|
18097482 |
2008 |
Childhood Burkitt Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Heterogeneous p53 mutations in a Burkitt lymphoma from an AIDS patient with monoclonal c-myc and VDJ rearrangements.
|
9399658 |
1997 |
Childhood Burkitt Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Immunohistochemical overexpression of p53 protein was found in 21% of NHL patients, with the highest incidence of p53 immunoreactivity in cases of Burkitt's lymphoma, follicle center lymphoma grade III, and diffuse large B-cell lymphoma.
|
12044054 |
2002 |
Childhood Burkitt Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In hematological malignancies, p53 is most often mutated in Burkitt's lymphoma, with p53 mutations present in 30 to 40% of tumor samples and in 70% of cell lines.
|
11723536 |
2001 |
Childhood Burkitt Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In order to better understand the mechanisms by which chemoresistance is mediated, non-hodgkin's lymphoma (NHL) patients overexpressing p53 mutant protein and resistant to CHOP chemotherapy, NHL patients without p53 overexpression and a Burkitt's lymphoma Raji cell line with p53 overexpression have been evaluated using fluorescent in situ hybridization (FISH) and comparative genomic hybridization (CGH).
|
21888455 |
2011 |
Childhood Burkitt Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, immunoglobulin variable (Ig V) region genes, c-myc re-arrangement and sequence and p53 status were analyzed in clones derived from a Burkitt's lymphoma cell line (LAM) in which it was previously demonstrated that Epstein-Barr virus (EBV) infection occurred late during lymphomagenesis.
|
11072243 |
2000 |
Childhood Burkitt Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we have examined the status of MDM2 and p53 in 20 BL cell lines.
|
9569028 |
1998 |
Childhood Burkitt Lymphoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Increased rate of transcription contributes to elevated expression of the mutant p53 gene in Burkitt's lymphoma cells.
|
8603415 |
1996 |
Childhood Burkitt Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
INZ(c) treatment decreased c-Myc expression at both mRNA and protein level, and suppressed c-Myc transcriptional activity in human Burkitt's lymphoma Raji cells with mutant p53.
|
25692307 |
2015 |
Childhood Burkitt Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
It is hypothesized that this difference with most tumors could be due to the fact that p53 mutations in BL and L3 ALL are generally associated with persistence of a normal residual p53 allele, contrary to what is observed in the majority of tumors.
|
7707106 |
1995 |
Childhood Burkitt Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Mutation in p53 was detected in all four Burkitt lymphoma cell lines as well as the three Burkitt lymphoma biopsy specimens.
|
8107196 |
1994 |
Childhood Burkitt Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Mutations of TP53 were detected in 11 of 49 (22.5%) patients and more specifically in 20% of Burkitt's lymphoma.
|
12890146 |
2003 |